These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 22404717)

  • 1. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
    Sigmon SC; Bisaga A; Nunes EV; O'Connor PG; Kosten T; Woody G
    Am J Drug Alcohol Abuse; 2012 May; 38(3):187-99. PubMed ID: 22404717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
    Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
    Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid antagonists with minimal sedation for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 6. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 8. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 9. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
    Mannelli P; Peindl KS; Lee T; Bhatia KS; Wu LT
    Curr Drug Abuse Rev; 2012 Mar; 5(1):52-63. PubMed ID: 22280332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED; Kleber HD; Whittington RA; Heitler NE
    JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in the treatment of opioid withdrawal.
    Srivastava AB; Mariani JJ; Levin FR
    Lancet; 2020 Jun; 395(10241):1938-1948. PubMed ID: 32563380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detoxification and treating opioid dependence.
    de Jong CJ
    JAMA; 2006 Feb; 295(8):887; author reply 887-8. PubMed ID: 16493098
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three methods of opioid detoxification in a primary care setting. A randomized trial.
    O'Connor PG; Carroll KM; Shi JM; Schottenfeld RS; Kosten TR; Rounsaville BJ
    Ann Intern Med; 1997 Oct; 127(7):526-30. PubMed ID: 9313020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications Development for Treatment of Opioid Use Disorder.
    Townsend EA; Negus SS; Banks ML
    Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 31932466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification.
    Rabinowitz J; Cohen H; Atias S
    Am J Addict; 2002; 11(1):52-6. PubMed ID: 11876583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.